Glucagon-like Peptide 1 Market Report 2026
Download Free Sample Buy Now
Glucagon like Peptide 1 Report Infographic Image
Item added to cart!

Published : February 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF
Purchase This Report

Glucagon-like Peptide 1 Market Report 2026

Global Outlook – By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of Administration (Oral, Parenteral, Other Routes), By End-Users (Hospitals, Specialty Clinics, Other End Users) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Glucagon-like Peptide 1 Market Overview

• Glucagon-like Peptide 1 market size has reached to $22.06 billion in 2025

• Expected to grow to $33.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%

• Growth Driver: Growing Health Awareness Fuels Demand For Glucagon-Like Peptide 1 (GLP-1) Market

• Market Trend: Novo Nordisk Introduces Wegovy Therapy For Weight Management

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Glucagon-like Peptide 1 Market?

Glucagon-like peptide 1 refers to a type of amino acid hormone of peptide that is produced in the L-cells of the intestinal epithelial endocrine. Glucagon-like peptide 1 is used to treat diseases and conditions such as diabetes and obesity respectively.

The main glucagon-like peptide 1 product types are trulicity, ozempic, victoza, rybelsus, and others. Trulicity refers to a prescription medicine that is injectable and is used to improve blood sugar. The various routes of administration are oral, parenteral, and others used in hospitals, specialty clinics, and others.

Glucagon-like Peptide 1 Market Global Report market report bar graph

What Is The Glucagon-like Peptide 1 Market Size and Share 2026?

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $22.06 billion in 2025 to $23.88 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing prevalence of diabetes, rising obesity rates globally, growing acceptance of injectable peptide therapies, expansion of endocrinology treatment options, availability of branded glp-1 drugs.

What Is The Glucagon-like Peptide 1 Market Growth Forecast?

The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $33.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing demand for weight management therapies, rising investments in peptide drug innovation, expansion of oral peptide delivery technologies, growing focus on chronic disease management, increasing adoption of personalized medicine. Major trends in the forecast period include rising adoption of GLP-1 therapies for obesity management, increasing development of oral glp-1 formulations, growing focus on long-acting peptide drugs, expansion of combination therapy approaches, enhanced patient-centric drug delivery systems.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Glucagon-like Peptide 1 Market Segmentation

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types

2) By Route of Administration: Oral, Parenteral, Other Routes

3) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)

2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)

3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)

4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)

5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems

What Is The Driver Of The Glucagon-like Peptide 1 Market?

Increasing emphasis on personalized medicine is expected to propel the growth of the glucagon-like peptide 1 (GLP-1) market going forward. Personalized medicine refers to a type of medication that prevents, detects, or treats disease using knowledge about a person's genes or proteins. Personalized medicine allows for the tailoring of GLP-1 formulations and dosages based on individual patient needs and preferences. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing emphasis on personalized medicine is driving the growth of the glucagon-like peptide 1 (GLP-1) market.

What Is The Driver Of The Glucagon-like Peptide 1 Market?

Increasing emphasis on personalized medicine is expected to propel the growth of the glucagon-like peptide 1 (GLP-1) market going forward. Personalized medicine refers to a type of medication that prevents, detects, or treats disease using knowledge about a person's genes or proteins. Personalized medicine allows for the tailoring of GLP-1 formulations and dosages based on individual patient needs and preferences. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing emphasis on personalized medicine is driving the growth of the glucagon-like peptide 1 (GLP-1) market.

Global Glucagon-like Peptide 1 Market Trends and Insights

Major companies operating in the glucagon-like peptide 1 market are focusing on developing technological advancements to enhance therapeutic efficacy, safety, and patient convenience in weight management and diabetes care. Glucagon-like peptide 1 (GLP-1) therapies are injectable peptide-based drugs that mimic the activity of the endogenous hormone GLP-1 to regulate appetite, glucose metabolism, and body weight. For instance, in March 2024, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched Wegovy, the first and only once-weekly GLP-1 therapy for weight management. The therapy, developed through the STEP Phase 3a clinical trial program, demonstrated a safe and well-tolerated profile and is designed to help people with obesity achieve and maintain weight loss. By introducing a convenient weekly dosing regimen, Wegovy enhances patient adherence and addresses the growing demand for innovative, effective obesity treatments.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Glucagon-like Peptide 1 Market?

In March 2024, Novo Holdings A/S, a Denmark-based investment company acquired Catalent Inc for $16.5 billion. With this acquisition, Novo Holdings aims to strengthen its footprint in the high-growth GLP-1 market by leveraging Catalent’s established infrastructure in fill-finish manufacturing, ensuring increased capacity to meet the rising demand for diabetes and weight-loss treatments. Catalent Inc is US-based biotechnology company specializes in advanced delivery technologies and development solutions for pharmaceuticals.

Regional Insights

North America was the largest region in the glucagon-like peptide 1 market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Glucagon-like Peptide 1 Market?

The glucagon-like peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glucagon-like Peptide 1 Market Report 2026?

The glucagon-like peptide 1 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide 1 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Glucagon-like Peptide 1 Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $23.88 billion
Revenue Forecast In 2035 $33.26 billion
Growth Rate CAGR of 8.2% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Product, Route of Administration, End-Users
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Novo Nordisk, Eli Lilly And Company, Pfizer Inc., AstraZeneca Plc, Sanofi S.A., Boehringer Ingelheim International GmbH, Merck And Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Johnson And Johnson, Amgen Inc., GlaxoSmithKline Plc, Novartis AG, Bayer AG, AbbVie Inc., Bristol Myers Squibb Company, Biocon Limited, Hanmi Pharmaceutical Co., Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Zealand Pharma A/S, Gan And Lee Pharmaceuticals Co., Ltd.
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Glucagon-like Peptide 1 Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Glucagon-like Peptide 1 Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Glucagon-like Peptide 1 Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Glucagon-like Peptide 1 Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Industry 4.0 & Intelligent Manufacturing

4.1.4 Sustainability, Climate Tech & Circular Economy

4.1.5 Artificial Intelligence & Autonomous Intelligence

4.2. Major Trends

4.2.1 Rising Adoption Of Glp-1 Therapies For Obesity Management

4.2.2 Increasing Development Of Oral Glp-1 Formulations

4.2.3 Growing Focus On Long-Acting Peptide Drugs

4.2.4 Expansion Of Combination Therapy Approaches

4.2.5 Enhanced Patient-Centric Drug Delivery Systems

5. Glucagon-like Peptide 1 Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Diabetes Care Centers

5.4 Pharmaceutical Companies

5.5 Research And Academic Institutes

6. Glucagon-like Peptide 1 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Glucagon-like Peptide 1 Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Glucagon-like Peptide 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Glucagon-like Peptide 1 Market Size, Comparisons And Growth Rate Analysis

7.3. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Glucagon-like Peptide 1 Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Glucagon-like Peptide 1 Market Segmentation

9.1. Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Trulicity, Ozempic, Victoza, Rybelsus, Other Types

9.2. Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Parenteral, Other Routes

9.3. Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Specialty Clinics, Other End Users

9.4. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)

9.5. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)

9.6. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)

9.7. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral tablet (3 mg, 7 mg, 14 mg)

9.8. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Experimental formulations, Combination products with other medications, Alternative delivery systems

10. Glucagon-like Peptide 1 Market Regional And Country Analysis

10.1. Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Glucagon-like Peptide 1 Market

11.1. Asia-Pacific Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Glucagon-like Peptide 1 Market

12.1. China Glucagon-like Peptide 1 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Glucagon-like Peptide 1 Market

13.1. India Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Glucagon-like Peptide 1 Market

14.1. Japan Glucagon-like Peptide 1 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Glucagon-like Peptide 1 Market

15.1. Australia Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Glucagon-like Peptide 1 Market

16.1. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Glucagon-like Peptide 1 Market

17.1. South Korea Glucagon-like Peptide 1 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Glucagon-like Peptide 1 Market

18.1. Taiwan Glucagon-like Peptide 1 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Glucagon-like Peptide 1 Market

19.1. South East Asia Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Glucagon-like Peptide 1 Market

20.1. Western Europe Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Glucagon-like Peptide 1 Market

21.1. UK Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Glucagon-like Peptide 1 Market

22.1. Germany Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Glucagon-like Peptide 1 Market

23.1. France Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Glucagon-like Peptide 1 Market

24.1. Italy Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Glucagon-like Peptide 1 Market

25.1. Spain Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Glucagon-like Peptide 1 Market

26.1. Eastern Europe Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Glucagon-like Peptide 1 Market

27.1. Russia Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Glucagon-like Peptide 1 Market

28.1. North America Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Glucagon-like Peptide 1 Market

29.1. USA Glucagon-like Peptide 1 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Glucagon-like Peptide 1 Market

30.1. Canada Glucagon-like Peptide 1 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Glucagon-like Peptide 1 Market

31.1. South America Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Glucagon-like Peptide 1 Market

32.1. Brazil Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Glucagon-like Peptide 1 Market

33.1. Middle East Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Glucagon-like Peptide 1 Market

34.1. Africa Glucagon-like Peptide 1 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Glucagon-like Peptide 1 Market Regulatory and Investment Landscape

36. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles

36.1. Glucagon-like Peptide 1 Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Glucagon-like Peptide 1 Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Glucagon-like Peptide 1 Market Company Profiles

36.3.1. Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Eli Lilly And Company Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

37. Glucagon-like Peptide 1 Market Other Major And Innovative Companies

Boehringer Ingelheim International GmbH, Merck And Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Johnson And Johnson, Amgen Inc., GlaxoSmithKline Plc, Novartis AG, Bayer AG, AbbVie Inc., Bristol Myers Squibb Company, Biocon Limited, Hanmi Pharmaceutical Co., Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd.

38. Global Glucagon-like Peptide 1 Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market

40. Glucagon-like Peptide 1 Market High Potential Countries, Segments and Strategies

40.1 Glucagon-like Peptide 1 Market In 2030 - Countries Offering Most New Opportunities

40.2 Glucagon-like Peptide 1 Market In 2030 - Segments Offering Most New Opportunities

40.3 Glucagon-like Peptide 1 Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Glucagon-like Peptide 1 Market, Overview Of Key Products - Product Examples
  • Table 2: Global Glucagon-like Peptide 1 Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Glucagon-like Peptide 1 Market, Supply Chain Analysis
  • Table 4: Global Glucagon-like Peptide 1 Market, Major Raw Material Providers
  • Table 5: Global Glucagon-like Peptide 1 Market, Major Resource Providers
  • Table 6: Global Glucagon-like Peptide 1 Market, Major Manufacturers (Suppliers)
  • Table 7: Global Glucagon-like Peptide 1 Market, Major Distributors And Channel Partners
  • Table 8: Global Glucagon-like Peptide 1 Market, Key Technologies & Future Trends
  • Table 9: Global Glucagon-like Peptide 1 Market, Major Trends
  • Table 10: Global Glucagon-like Peptide 1 Market, Major End Users
  • Table 11: Global Glucagon-like Peptide 1 Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Glucagon-like Peptide 1 Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Glucagon-like Peptide 1 Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Glucagon-like Peptide 1 Market - TAM, US$ Billion, 2025
  • Table 15: Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Global Glucagon-like Peptide 1 Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 98: Global Glucagon-like Peptide 1 Market - Company Scoring Matrix
  • Table 99: Novo Nordisk Financial Performance
  • Table 100: Eli Lilly And Company Financial Performance
  • Table 101: Pfizer Inc. Financial Performance
  • Table 102: AstraZeneca Plc Financial Performance
  • Table 103: Sanofi S.A. Financial Performance
  • Table 104: Global Glucagon-like Peptide 1 Market, Competitive Benchmarking (In USD Billions)
  • Table 105: Global Glucagon-like Peptide 1 Market, Competitive Dashboard
  • Table 106: Global Glucagon-like Peptide 1 Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 107: Global, Glucagon-like Peptide 1 Market Size Gain ($ Billion), Segmentation By Product, 2025 – 2030
  • Table 108: Global, Glucagon-like Peptide 1 Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030
  • Table 109: Global, Glucagon-like Peptide 1 Market Size Gain ($ Billion), Segmentation By End-Users, 2025 – 2030

List Of Figures

    Figure 1: Global Glucagon-like Peptide 1 Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Glucagon-like Peptide 1 Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Glucagon-like Peptide 1 Market, Supply Chain Analysis
  • Figure 4: Global Glucagon-like Peptide 1 Market, Major Raw Material Providers
  • Figure 5: Global Glucagon-like Peptide 1 Market, Major Resource Providers
  • Figure 6: Global Glucagon-like Peptide 1 Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Glucagon-like Peptide 1 Market, Major Distributors And Channel Partners
  • Figure 8: Global Glucagon-like Peptide 1 Market, Key Technologies & Future Trends
  • Figure 9: Global Glucagon-like Peptide 1 Market, Major Trends
  • Figure 10: Global Glucagon-like Peptide 1 Market, Major End Users
  • Figure 11: Global Glucagon-like Peptide 1 Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Glucagon-like Peptide 1 Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Glucagon-like Peptide 1 Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Glucagon-like Peptide 1 Market - TAM, US$ Billion, 2025
  • Figure 15: Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Global Glucagon-like Peptide 1 Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 98: Global Glucagon-like Peptide 1 Market - Company Scoring Matrix
  • Figure 99: Novo Nordisk Financial Performance
  • Figure 100: Eli Lilly And Company Financial Performance
  • Figure 101: Pfizer Inc. Financial Performance
  • Figure 102: AstraZeneca Plc Financial Performance
  • Figure 103: Sanofi S.A. Financial Performance
  • Figure 104: Global Glucagon-like Peptide 1 Market, Competitive Benchmarking (In USD Billions)
  • Figure 105: Global Glucagon-like Peptide 1 Market, Competitive Dashboard
  • Figure 106: Global Glucagon-like Peptide 1 Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 107: Global, Glucagon-like Peptide 1 Market Size Gain ($ Billion), Segmentation By Product, 2025 – 2030
  • Figure 108: Global, Glucagon-like Peptide 1 Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030
  • Figure 109: Global, Glucagon-like Peptide 1 Market Size Gain ($ Billion), Segmentation By End-Users, 2025 – 2030

Explore the key trends, growth drivers, and market forecast for the global circular polymer market through 2029.

Read More About Explore the key trends, growth drivers, and market forecast for the global circular polymer market through 2029.

Examine TBRC’s analysis of market growth, applications, and regional demand trends for Hypochlorous Acid.

Read More About Examine TBRC’s analysis of market growth, applications, and regional demand trends for Hypochlorous Acid.

Understanding Key Drivers and Growth Opportunities in the Alcohol Based Disinfectants Market: Trends and Market Size Insights

Read More About Understanding Key Drivers and Growth Opportunities in the Alcohol Based Disinfectants Market: Trends and Market Size Insights

Glucagon-like Peptide 1 Market Report 2026 - Global Outlook – By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of Administration (Oral, Parenteral, Other Routes), By End-Users (Hospitals, Special...

Peptide Therapeutics Market Report 2026 - Global Outlook – By Type (Generic, Branded), By Route of Administration (Parenteral, Mucosal, Oral, Transdermal ), By Application (Cancer, Cardiovascular Diseases, Central Nervou...

Peptide Synthesis Market Report 2026 - Global Outlook – By Product And Service (Reagents, Equipment, Services), By Technology (Solid-Phase Peptide Synthesis, Solution-Phase Peptide Synthesis, Hybrid And Recombinant Techn...

Peptide Based Metabolic Disorders Therapeutics Market Report 2026 - Global Outlook – By Drug Type (Liraglutide, Exenatide, Other Drug Type), By Application (Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterol...

G-Protein Coupled Receptors Market Report 2026 - Global Outlook – By Product (Cell Lines, Detection Kits, Cell Culture Reagents, Ligands), By Assay (CAMP Functional Assays, Calcium Functional Assays, ß-Arrestin Functiona...

Cell Penetrating Peptide Market Report 2026 - Global Outlook – By Type (Synthetic Cell Penetrating Peptides, Protein-Derived Cell Penetrating Peptides, Chimeric Cell Penetrating Peptides), By Application (Drug Delivery, ...

GLP-1 Receptor Agonist Market Report 2026 - Global Outlook – By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs ), By Route Of Administration (Parenteral, Oral ), By End Users (Hospitals, Surgi...

Aminoglycosides Market Report 2026 - Global Outlook – By Product (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Streptomycin, Kanamycin, Other Products), By Route Of Administration (Injectables (Parenteral), F...

Frequently Asked Questions

The Glucagon-like Peptide 1 Market Global Report 2026 market was valued at $22.06 billion in 2025, increased to $22.06 billion in 2026, and is projected to reach $33.26 billion by 2030. request a sample here

The expected CAGR for the Glucagon-like Peptide 1 Market Global Report 2026 market during the forecast period 2025–2030 is 8.63%. request a sample here

Major growth driver of the market includes: Growing Health Awareness Fuels Demand For Glucagon-Like Peptide 1 (GLP-1) Market in the Glucagon-like Peptide 1 Market Global Report 2026 market. For further insights on this market, request a sample here

The glucagon-like peptide 1 market covered in this report is segmented –
1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems request a sample here

Major trend in this market includes: Novo Nordisk Introduces Wegovy Therapy For Weight Management For further insights on this market, request a sample here.

Major companies operating in the Glucagon-like Peptide 1 Market Global Report 2026 market are Major companies operating in the glucagon-like peptide 1 market are Novo Nordisk, Eli Lilly And Company, Pfizer Inc., AstraZeneca Plc, Sanofi S.A., Boehringer Ingelheim International GmbH, Merck And Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Johnson And Johnson, Amgen Inc., GlaxoSmithKline Plc, Novartis AG, Bayer AG, AbbVie Inc., Bristol Myers Squibb Company, Biocon Limited, Hanmi Pharmaceutical Co., Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Zealand Pharma A/S, Gan And Lee Pharmaceuticals Co., Ltd. request a sample here.

North America was the largest region in the glucagon-like peptide 1 market in 2025. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us